Design and synthesis of new potent inhibitors of farnesyl pyrophosphate synthase

Current Drug Discovery Technologies

Volumn 11, Issue 2, 2014, Pages 133-144

  Prokopenko, Volodymyr ^a   Kovalishyn, Vasyl ^a   Shevchuk, Michael ^a   Kopernyk, Iryna ^a   Metelytsia, Larysa ^a   Romanenko, Vadim ^a   Mogilevich, Sergey ^a   Kukhar, Valery ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY AND PETROCHEMISTRY   (Ukraine)

Author keywords

Artificial neural networks; Drug design; Fungistatic activity; Michael addition; Nitrogen containing bisphosphonates; QSAR

Indexed keywords

2 (2 MORPHOLINOETHYLAMINO) ETHYLIDENE 1,1 BISPHOSPHONIC ACID; 2 (2,2,3,3,4,4,5,5 OCTAFLUOROPENTYLAMINO)ETHYLIDENE 1,1 BISPHOSPHONIC ACID; 2 (BUTYLAMINO)ETHYLIDENE 1,1 BISPHOSPHONIC ACID; 2 (CYCLOHEXYLAMINO)ETHYLIDENE 1,1 BISPHOSPHONIC ACID; 2 [4 (ETHOXYCARBONYL) PIPERAZIN 1 YL]ETHYLIDENE 1,1 BISPHOSPHONIC ACID; 2 [DIETHOXYPHOSPHORYL(4 METHOXYPHENYL) METHYLAMINO] ETHYLIDENEBISPHOSPHONIC ACID; AMMONIUM 2 (PYRIDIN 2 YLAMINO)ETHYLIDENE 1,1 BISPHOSPHONATE; ANTIFUNGAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; FARNESYL PYROPHOSPHATE SYNTHASE; FLUCONAZOLE; SYNTHETASE; UNCLASSIFIED DRUG; GERANYLTRANSFERASE;

ANTIFUNGAL ACTIVITY; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOLOGICAL ACTIVITY; CANDIDA ALBICANS; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; EVALUATION STUDY; HUMAN; MICHAEL ADDITION; MYCOSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOM FOREST; SENSITIVITY ANALYSIS; ANTAGONISTS AND INHIBITORS; ARTIFICIAL INTELLIGENCE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; LEISHMANIA MAJOR;

ANTIFUNGAL AGENTS; ARTIFICIAL INTELLIGENCE; CANDIDA ALBICANS; DIPHOSPHONATES; DRUG DESIGN; GERANYLTRANSTRANSFERASE; LEISHMANIA MAJOR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84900867550     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/15701638113106660041     Document Type: Article

References (49)

1. Berlicki L, Kafarski P. Computer-Aided Analysis and Design of Phosphonic and Phosphinic Enzyme Inhibitors as Potential Drugs and Agrochemicals. Curr Org Chem 2005; 9: 1829.
2. Reszka AA, Rodan A. Nitrogen-Containing Bisphosphonate Mechanism of Action. Mini-Rev Med Chem 2004; 4: 711-9.
3. Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity. Cancer Res 2005; 65: 4971-4.
4. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo ClinProc 2008; 83: 1032-45.
5. Simoni D, Gebbia N, Invidiata FP, et al. Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in vivo Antitumor Activity Through a-T Lymphocytes-Mediated Activation Mechanism. J Med Chem 2008; 51: 6800-7.
6. Sanders JM, Ghosh S, Chan JM, et al. Quantitative Structure Activity Relationships for T Cell Activation by Bisphosphonates. J Med Chem 2004; 47: 375-84.
7. Szajnman SH, GarcíaLiñares GE, Li ZH, et al. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosomacruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.Bioorg Med Chem 2008; 16: 3283-90.
8. Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit the growth of Trypanosomacruzi, Leismaniadonovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy. J MedChem 2001, 44: 909-16.
9. Gebre-Hiwot A, Frommel D. The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis. J AntimicrobChemother 1993; 32: 837-42.
10. Babu BH, Prasad GS, Babu MFS, Haranath P, Reddy SH, Raju CN. Synthesis and bioactivity of novel bisphosphonate derivatives. Heterocycles 2008; 75: 611-18.
11. Reddy MVN, Reddy KRKK, Reddy CB, Kumar BS, Reddy CS, Reddy CD. Synthesis and antimicrobial activity of bisphosphonates. J Chem Res 2009; 4: 258-60.
12. Kunda UM, Balam SK, Nemallapudi BR, Chereddy SS, Nayak SK, Cirandur SR. Facile synthesis, antioxidant and antimicrobial activity of amino methylene bisphosphonates.Chem Pharm Bull 2012; 60: 104-9.
13. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
14. Sanders JM, Gómez AO, Mao J, et al. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.J Med Chem 2003; 46: 5171-83.
15. Sanders JM, Song Y, Chan JM, et al. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem 2005; 48: 2957-63.
16. RCSB Protein Data Bank. http://www.rcsb.org/. Accessed on 1 September 2013.
17. Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A. QSAR Modeling of the Blood-Brain Barrier Permeability for Diverse OrganicCompounds. Pharm Res 2008; 25: 1902-14.
18. Prathipati P, Ma NL, Keller TH. Global Bayesian Models for the Prioritization of Antitubercular Agents. J Chem Inf Model 2008; 48: 2362-70.
19. Sheridan RP, Feuston BP, Maiorov VN, Kearsley SK. Similarity to Molecules in the Training Set Is a Good Discriminator for Prediction Accuracy in QSAR. J Chem Inf Comput Sci 2004; 44: 1912-28.
20. Ghosh S, Chan JM, Lea CR, et al. Effects of bisphosphonates on the growth of Entamoebahistolytica and Plasmodium species in vitro and in vivo. J Med Chem 2004; 47:175-87.
21. Hudock MP, Sanz-Rodríguez CE, Song Y, et al. Inhibition of Trypanosomacruzi hexokinase by bisphosphonates. J Med Chem 2006; 49: 215-23.
22. Ling Y, Li ZH, Miranda K, Oldfield E, Moreno SN. The farnesyldiphosphate/ geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem 2007; 282: 30804-16.
23. ChemAxon. https://www.chemaxon.com/.Accessed on 1 March, 2013.
24. Talete SRLhttp://www.talete.mi.it/products/dragon-description.htm. Accessed on1 April 2013.
25. Todeschini R, Consonni V.Handbook of Molecular Descriptors. Wiley-VCH Verlag GmbH: Weinheim2008.
26. Tetko IV. Neural network studies. 4. Introduction to associative neural network. J Chem Inf Comput Sci 2002; 42: 717-28.
27. Tetko IV, TanchukVYu, Chentsova NP, et al. HIV-1 Reverse Transcriptase Inhibitor Design Using Artificial Neural Networks. J Med Chem 1994; 37: 2520-26.
28. Tollenaere T, SuperSAB. Fast Adaptive Back Propagation with Good Scaling Properties. Neural Networks 1990; 3: 561-73.
29. Tetko IV, Livingstone DJ, Luik AI. Neural Network Studies. 1. Comparison of Overfitting and Overtraining. J Chem Inf Comput Sci 1995; 35: 826-33.
30. Tetko IV, Villa AEP. Efficient Partition of Learning Data Sets for Neural Network Training. Neural Networks 1997; 10: 1361-74.
31. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Chapman & Hall/CRC: Boca Raton1984.
32. R Development Core Team (2004). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0.Available at: Http://www.R-project.org (last accessed in April 2013). Fortran original by Leo Breiman, Adele Cutler, R port by Andy Liaw and Matthew Wiener. (2004).
33. LeCun Y, Dencer JS, Solla SA. Optimal Brain Damage.In: Touretzky DS, Ed. NIPS 2.San Mateo: Morgan Kaufmann 1990; pp. 598-605.
34. Chauvin YA.Back-Propagation Algorithm with Optimal Use of Hidden Units.In: Touretzky DS, Ed. NIPS 1.San Mateo : Morgan Kaufmann1989; pp.519-526.
35. Tetko IV, Villa AEP, and Livingstone DJ. Neural network studies. 2. Variable selection. J Chem Inf Comput Sci 1996; 36: 794-803.
36. Kovalishyn VV, Tetko IV, Luik AI, Kholodovych VV, Villa AEP, Livingstone DJ. Neural network studies. 3. Variable selection in the cascade-correlation learning architecture. J Chem Inf Comput Sci 1998; 38: 651-59.
37. Mahobia NK, Patel RD, Sheikh NW, Singh SK, Mishra A, Dhardubey R. Validation Method Used In Quantitative Structure Activity Relationship. Der Pharma Chemica 2010; 2: 260-71.
38. Kennard RW and Stone LA. Computer aided design of experiments. Technometrics1969; 11: 137-47.
39. Jonhos NN, Leone FG. Statistic and Experimental Design in Engineering and the Physical Sciences. John Wiley & Sons: New York 1977.
40. Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am ChemSoc 1988; 110: 5959-67.
41. Romanenko VD, Shevchuk MV, Kukhar VP. Application of Silicon-based Methodologies for the Synthesis of Functionalized Mono-and Bisphosphonic Acids.Curr Org Chem 2011; 15: 2774-801.
42. Shevchuk MV, Sotiropoulos JM, Miqueu K, Romanenko VD, Kukhar VP. Tetrakis (trimethylsilyl) Ethenylidene-1,1-bisphosphonate: A Mild and Convenient Michael Acceptor for the Synthesis of 2-Aminoethylidene-1,1-bisphosphonic Acids and Their Potassium Salts. Synlett 2011; 10: 1370-4.
43. Montavetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J BiolChem 2001; 276: 33930-37.
44. Szajnman SH, Bailey BN, Docampo R, Rodriguez JB. Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorgand Med Chem Letters 2001; 11: 789-92.
45. Yin F, Cao R, Goddard A, Zhang Y, Oldfield E. Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase. J Am Chem Soc 2006; 128: 3524-5.
46. Degenhardt CR, Burdsall DC. Synthesis of ethenylidenebis (phosphonic acid) and its tetraalkyl esters. J Org Chem 1986; 51: 3488-90.
47. Carnahan JE, Sampson HJ. Fluorocarbon Compounds and Preparation of Same, US Patent 2,646,449, 1953.
48. Ghosh S, Chan JM, Lea CR, et al. Effects of Bisphosphonates on the Growth of Entamoebahistolytica and Plasmodium Species in vitro and in vivo. J Med Chem 2004; 47: 175-87.
49. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin-Pathol 1966; 45: 493-6.